Literature DB >> 2054238

Atherosclerosis: inhibition of regression as therapeutic possibilities.

M J Davies1, D M Krikler, D Katz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054238      PMCID: PMC1024670          DOI: 10.1136/hrt.65.6.302

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  73 in total

1.  An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.

Authors:  I Holme
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

2.  Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. I. Characterization of cellular lipid metabolism.

Authors:  G Schmitz; H Robenek; M Beuck; R Krause; A Schurek; R Niemann
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

3.  Occurrence of stroke in a nonhuman primate model of cerebrovascular disease.

Authors:  S Prusty; T Kemper; M B Moss; W Hollander
Journal:  Stroke       Date:  1988-01       Impact factor: 7.914

4.  Nifedipine-suppressed atherosclerosis in cholesterol-fed rabbits but not in Watanabe heritable hyperlipidemic rabbits.

Authors:  Y Ishikawa; N Watanabe; R Okamoto; Y Watanabe; H Fukuzaki
Journal:  Atherosclerosis       Date:  1987-03       Impact factor: 5.162

5.  George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

Authors:  D M Small
Journal:  Arteriosclerosis       Date:  1988 Mar-Apr

6.  Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum.

Authors:  O Stein; G Halperin; Y Stein
Journal:  Arteriosclerosis       Date:  1987 Nov-Dec

7.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

8.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

Authors:  T E Carew; D C Schwenke; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

9.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.

Authors:  T Kita; Y Nagano; M Yokode; K Ishii; N Kume; A Ooshima; H Yoshida; C Kawai
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 10.  The pathogenesis of atherosclerosis: atherogenesis and inflammation.

Authors:  J M Munro; R S Cotran
Journal:  Lab Invest       Date:  1988-03       Impact factor: 5.662

View more
  5 in total

1.  Frequency of citation and outcome of cholesterol lowering trials.

Authors:  J F Goodwin
Journal:  BMJ       Date:  1992-08-15

2.  Preventing coronary heart disease.

Authors:  J F Goodwin; I Sharp
Journal:  BMJ       Date:  1992-04-18

Review 3.  Angiographic trials of lipid-lowering therapy: end of an era?

Authors:  G R Thompson
Journal:  Br Heart J       Date:  1995-10

Review 4.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Authors:  T R Pedersen; J A Tobert
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

5.  Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT.

Authors:  S Jost; J Deckers; W Rafflenbeul; J H Reiber; P Nikutta; B Wiese; H Hecker; P Lippolt; M Riedel; C W Nolte
Journal:  Int J Card Imaging       Date:  1993-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.